Angelica gigas Nakai (Korean Dang-gui) Root Alcoholic Extracts in Health Promotion and Disease Therapy – active Phytochemicals and In Vivo Molecular Targets

Pharmaceutical Research, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 8, 2025

Abstract Angelica gigas Nakai (AGN) root is a medicinal herbal widely used in traditional medicine Korea. AGN ethanolic extracts have been marketed as dietary supplements the United States for memory health and pain management. We recently reviewed pharmacokinetics (PK) first-pass hepatic metabolism of ingested humans signature pyranocoumarins decursin (D, C max 1x), decursinol angelate (DA, ~ 10x) their common botanical precursor metabolite (DOH, 1000x). Here we update vivo activities and/or its furanocoumarin nodakenin cancer, pain, loss, cerebral ischemia reperfusion stroke, metabolic syndrome vascular endothelial dysfunctions, anxiety, sleep disorder, epilepsy, inflammatory bowel disease, osteoporosis osteoarthritis. Given polypharmacology nature, pertinent mechanisms action are likely misrepresented by many cell culture studies that did not consider drug knowledge. report here Rho -associated protein kinases (ROCK1/2) novel targets DA DOH. Combining with published inhibitory activity DOH on acetylcholinesterase, agonist antagonist/degrader DA/D androgen estrogen receptors, D/DA promoting glutamic acid decarboxylase (GAD)- gamma-aminobutyric (GABA) axis inhibition glutamate dehydrogenase (GDH), monoamine oxidase-A (MAO-A) transient receptor potential vanilloid 1 (TRPV1), postulate contributions to neuro-cognitive, metabolic, oncologic, other beneficial bioactivities extracts. A clinical trial being planned an extract manage side effects deprivation therapy prostate cancer patients.

Language: Английский

Inhibitory Effects of Reynoutria japonica Houtt. on Pain and Cartilage Breakdown in Osteoarthritis Based on Its Multifaceted Anti-Inflammatory Activity: An In Vivo and In Vitro Approach

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(19), P. 10647 - 10647

Published: Oct. 3, 2024

In the past 30 years, number of years lived with disability due to osteoarthritis (OA) has doubled, making it an increasing global health burden. To address this issue, interventions that inhibit progressive pathology driven by age-related low-grade inflammation, primary mechanism OA, are being actively pursued. Recent investigations have focused on modulating inflammatory disease as a therapeutic target. However, no agent successfully halted disease’s progression or reversed its irreversible course. Reynoutria japonica Houtt. (RJ), promising East Asian herbal medicine, been utilized for several diseases potent anti-inflammatory activity. This study aims determine RJ’s capacity OA symptoms and associated exploring potential further development. vivo in vitro experiments demonstrated anti-OA activity modulation multifaceted targets. RJ significantly inhibited pain, gait deterioration, cartilage destruction monosodium iodoacetate-induced rat model, analgesic effect confirmed acetic acid-induced writhing model. exhibited consistent against multiple targets serum model lipopolysaccharide-induced RAW 264.7 cells. The inhibition cytokines, including interleukin-1β, interleukin-6, matrix metalloproteinase-13, tumor necrosis factor-α, nitric oxide synthase 2, suggests alleviation manifestations relates These results indicate merits investigation disease-modifying drug candidate targeting OA’s pathology. characterize pharmacological properties RJ, future studies expanded designs warranted.

Language: Английский

Mechanistic Exploration of Smilax glabra Roxb. in Osteoarthritis: Insights from Network Pharmacology, Molecular Docking, and In Vitro Validation

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(10), P. 1285 - 1285

Published: Sept. 27, 2024

: Arthritis, a debilitating joint disease, remains significant global health burden. This study uncovers the therapeutic potential of medicinal plant

Language: Английский